Status:
COMPLETED
Identification of Predictive Biomarkers
Lead Sponsor:
Martini-Klinik am UKE GmbH
Collaborating Sponsors:
Erich und Gertrud Roggenbuck-Stiftung zur Förderung der Krebsforschung
Conditions:
Prostate Cancer Recurrent
Eligibility:
MALE
18-80 years
Phase:
NA
Brief Summary
Molecular nuclear imaging in prostate cancer has made significant progress in the last few years. The introduction of tracers that target the prostate-specific membrane antigen (PSMA) has profoundly i...
Detailed Description
As mentioned before, current data on salvage lymphadenectomy in prostate cancer is very limited and stems mainly from retrospective series. Prospective studies are not available. Furthermore, most of ...
Eligibility Criteria
Inclusion
- Patients in good general health and an expected life expectancy of \> 10 years
- Diagnosis of prostate cancer relapse
- Evidence of positive lymph nodes or soft tissue metastases as seen in PSMA PET
Exclusion
- Contraindication for a surgical procedure
- Clinical suspicion of systemic disease as determined by PSMA PET
- PSMA PET examination older than 4 months at time of surgery
Key Trial Info
Start Date :
March 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 5 2023
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04324983
Start Date
March 1 2020
End Date
April 5 2023
Last Update
April 12 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Martini-Klinik am UKE GmbH
Hamburg, Germany, 20246